Advertisement
Research Article

Optimal Management of High-Risk T1G3 Bladder Cancer: A Decision Analysis

  • Girish S Kulkarni,

    Affiliations: Division of Urology, Department of Surgical Oncology, University of Toronto, Toronto, Ontario, Canada, Department of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada

    X
  • Antonio Finelli,

    Affiliations: Division of Urology, Department of Surgical Oncology, University of Toronto, Toronto, Ontario, Canada, Department of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada

    X
  • Neil E Fleshner,

    Affiliation: Division of Urology, Department of Surgical Oncology, University of Toronto, Toronto, Ontario, Canada

    X
  • Michael A. S Jewett,

    Affiliation: Division of Urology, Department of Surgical Oncology, University of Toronto, Toronto, Ontario, Canada

    X
  • Steven R Lopushinsky,

    Affiliation: Department of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada

    X
  • Shabbir M. H Alibhai mail

    To whom correspondence should be addressed. E-mail: shabbir.alibhai@uhn.on.ca

    Affiliations: Department of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada, Division of General Internal Medicine and Clinical Epidemiology, University of Toronto, Toronto, Ontario, Canada

    X
  • Published: September 25, 2007
  • DOI: 10.1371/journal.pmed.0040284

About the Authors

Girish S Kulkarni, Antonio Finelli, Neil E Fleshner, Michael A. S Jewett
Division of Urology, Department of Surgical Oncology, University of Toronto, Toronto, Ontario, Canada
Girish S Kulkarni, Antonio Finelli, Steven R Lopushinsky, Shabbir M. H Alibhai
Department of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada
Shabbir M. H Alibhai
Division of General Internal Medicine and Clinical Epidemiology, University of Toronto, Toronto, Ontario, Canada

Corresponding Author

Email: shabbir.alibhai@uhn.on.ca

Competing Interests

MASJ is a consultant to and investigator with Viventia Biotech Inc, Bioniche Inc.

Author Contributions

GSK was responsible for conception and design; acquisition, analysis, and interpretation of data; drafting of manuscript; critical revision of the manuscript for important intellectual content; statistical analyses; securing funding; and approval of final manuscript. AF was responsible for conception and design, acquisition of data, analysis and interpretation of data, drafting of manuscript, critical revision of the manuscript for important intellectual content, statistical analyses, and approval of final manuscript. NEF was responsible for conception and design; analysis and interpretation of data; critical revision of the manuscript for important intellectual content; administrative, technical, and material support; supervision; and approval of final manuscript. MASJ was responsible for analysis and interpretation of data; critical revision of the manuscript for important intellectual content; administrative, technical, and material support; and approval of final manuscript. SRL was responsible for analysis and interpretation of data, drafting of manuscript, critical revision of the manuscript for important intellectual content, and approval of final manuscript. SMHA was responsible for conception and design, analysis and interpretation of data, drafting of manuscript, critical revision of the manuscript for important intellectual content, statistical analyses, supervision, and approval of final manuscript.